Results of Operations and Financial Condition

Business Context and Reporting Period

This Form 8-K is filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp) on October 26, 2023. The report announces the financial results for the three and nine months ended September 30, 2023. The detailed results are contained in a press release attached as Exhibit 99.1.

Key Financial Metrics

The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the body of this 8-K document.

Material Changes

No specific material changes versus prior periods are detailed in the text of this filing. The document serves solely as a notification that results have been reported and directs readers to the attached exhibit for comparative data.

Guidance, Outlook, and Risks

The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is "furnished" and not "filed" under the Exchange Act. Consequently, this information is not subject to Section 18 liabilities and shall not be incorporated by reference into other filings. No specific guidance, outlook, or risk factors are enumerated in the text provided.

Investor Verification Checklist

  • Verify the correct registrant name is Ekso Bionics Holdings, Inc. (Ticker: EKSO), not Chronoscale Holdings Corp.
  • Review Exhibit 99.1 (Press Release dated October 26, 2023) for actual revenue, net loss, and cash flow figures.
  • Confirm the reporting period covers the three and nine months ended September 30, 2023.
  • Note that the financial data in this specific 8-K text is not legally "filed" for liability purposes under Section 18 of the Exchange Act.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.